Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F21%3A10428476" target="_blank" >RIV/00216208:11110/21:10428476 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/21:10428476
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=j0nCJ-FEjM" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=j0nCJ-FEjM</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1212/NXI.0000000000000979" target="_blank" >10.1212/NXI.0000000000000979</a>
Alternative languages
Result language
angličtina
Original language name
Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis
Original language description
Objective: To describe the dynamics of brain volume loss (BVL) at different stages of relapsing-remitting multiple sclerosis (RRMS), to describe the association between BVL and clinical measures, and to investigate an effect of treatment escalation on the rate of BVL. Methods: Together, 1903 patients predominantly with RRMS from the Avonex-Steroids-Azathioprine cohort (N = 166), the study of early IFN-β1a treatment cohort (N = 180), and the quantitative MRI cohort (N = 1,557) with >=2 MRI scans and >=1-year of follow-up were included. Brain MRI scans (N = 7,203) were performed using a single 1.5-T machine. Relationships between age or disease duration and global and tissue-specific BVL rates were analyzed using mixed models. Results: Age was not associated with the rate of BVL (β = -0.003; Cohen f2 = 0.0005; adjusted p = 0.39). Although disease duration was associated with the rate of BVL, its effect on the BVL rate was minimal (β = -0.012; Cohen f2 = 0.004; adjusted p = 4 x 10-5). Analysis of association between tissue-specific brain volume changes and age (β = -0.019 to -0.011; adjusted p = 0.028-1.00) or disease duration (β = -0.028 to -0.008; adjusted p = 0.16-0.96) confirmed these results. Although increase in the relapse rate (β = 0.10; adjusted p = 9 x 10-9), Expanded Disability Status Scale (EDSS; β = 0.17; adjusted p = 8 x 10-5), and EDSS change (β = 0.15; adjusted p = 2 x 10-5) were associated with accelerated rate of BVL, their effect on the rate of BVL was minimal (all Cohen f2 <= 0.007). In 94 patients who escalated therapy, the rate of BVL decreased following treatment escalation by 0.29% (β = -0.29; Cohen f2 = 0.133; p = 5.5 x 10-8). Conclusions: The rate of BVL is relatively stable throughout the course of RRMS. The accelerated BVL is weakly associated with concurrent higher disease activity, and timely escalation to high-efficacy immunotherapy helps decrease the rate of BVL.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30103 - Neurosciences (including psychophysiology)
Result continuities
Project
<a href="/en/project/NV18-04-00168" target="_blank" >NV18-04-00168: Complex characteristics of spinal cord pathology on MRI and its correlation with clinical disability and serum neurofilament levels in multiple sclerosis patients</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Neurology: Neuroimmunology & Neuroinflammation
ISSN
2332-7812
e-ISSN
—
Volume of the periodical
8
Issue of the periodical within the volume
3
Country of publishing house
US - UNITED STATES
Number of pages
12
Pages from-to
e979
UT code for WoS article
000658833000009
EID of the result in the Scopus database
2-s2.0-85103146211